Literature DB >> 10442907

Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma.

M W Wilson1, J L Hungerford.   

Abstract

PURPOSE: To compare the efficacy of iodine-125 (125I) and ruthenium-106 (106Ru) episcleral plaque radiation therapy and proton beam radiation therapy (PBRT) in the treatment of choroidal melanoma.
DESIGN: A retrospective, nonrandomized comparative study.
METHODS: Charts of patients treated with 125I, 106Ru, and PBRT for choroidal melanoma between January 1988 and June 1996 at St. Bartholomew's Hospital and Moorfields Eye Hospitals were reviewed. MAIN OUTCOME MEASURE: Local control of choroidal melanomas after 125I, 106Ru, or PBRT.
RESULTS: A total of 597 patients were identified (125I = 190, 106Ru = 140, PBRT = 267). Patients treated with 106Ru had a significantly greater risk of local tumor recurrence than did patients treated with either 125I (P = 0.0133; confidence interval [CI], 1.26-7.02; risk ratio, 2.97) or PBRT (P = 0.0097; CI, 1.30-6.66; risk ratio, 2.94). A stepwise Cox proportional hazard model found maximal basal diameter to be a significant covariate (P = 0.0033).
CONCLUSION: Patients treated with 106Ru had a significantly greater risk of local tumor recurrence than did those patients treated with either 125I or PBRT.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10442907     DOI: 10.1016/S0161-6420(99)90456-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  34 in total

1.  Where is the superiority of proton radiation for ocular tumours?

Authors:  Nikolaos E Bechrakis; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-07       Impact factor: 3.117

Review 2.  Lasers for the treatment of intraocular tumors.

Authors:  Samuel K Houston; Charles C Wykoff; Audina M Berrocal; Ditte J Hess; Timothy G Murray
Journal:  Lasers Med Sci       Date:  2013-05       Impact factor: 3.161

3.  Radiotherapy in ophthalmology : 2004 Jules Gonin lecture of the Retina Research Foundation.

Authors:  Leonidas Zografos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-07       Impact factor: 3.117

4.  Finger's "slotted" eye plaque for radiation therapy: treatment of juxtapapillary and circumpapillary intraocular tumours.

Authors:  Paul T Finger
Journal:  Br J Ophthalmol       Date:  2007-02-27       Impact factor: 4.638

5.  Incidence and indications for pars plana vitrectomy following the treatment of posterior uveal melanomas in Scotland.

Authors:  S N Chia; H B Smith; H M Hammer; E G Kemp
Journal:  Eye (Lond)       Date:  2015-03-20       Impact factor: 3.775

6.  18 years' experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma.

Authors:  R van Ginderdeuren; E van Limbergen; W Spileers
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

7.  Cepharanthine exerts antitumor activity on choroidal melanoma by reactive oxygen species production and c-Jun N-terminal kinase activation.

Authors:  Qi Zhu; Baofeng Guo; Linlin Chen; Qiuye Ji; Hang Liang; Naiyan Wen; Ling Zhang
Journal:  Oncol Lett       Date:  2017-03-29       Impact factor: 2.967

8.  Episcleral brachytherapy for uveal melanoma: analysis of 136 cases.

Authors:  Ciro García-Álvarez; María Antonia Saornil; Francisco López-Lara; Ana Almaraz; María Fe Muñoz; Jesús Frutos-Baraja; Yerena Muiños
Journal:  Clin Transl Oncol       Date:  2012-05       Impact factor: 3.405

Review 9.  The effectiveness and safety of proton radiation therapy for indications of the eye : a systematic review.

Authors:  Geertruida E Bekkering; Anne W S Rutjes; Vasiliy V Vlassov; Daniel M Aebersold; Konrade von Bremen; Peter Jüni; Jos Kleijnen
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

10.  Combined plaque radiotherapy and transpupillary thermotherapy in choroidal melanoma: 5 years' experience.

Authors:  Y M Bartlema; J A Oosterhuis; J G Journée-De Korver; R E Tjho-Heslinga; J E E Keunen
Journal:  Br J Ophthalmol       Date:  2003-11       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.